Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jan 24;61(2):e01582-16.
doi: 10.1128/AAC.01582-16. Print 2017 Feb.

Low Caspofungin Exposure in Patients in Intensive Care Units

Kim C M van der Elst  1 , Anette Veringa  1 , Jan G Zijlstra  2 , Albertus Beishuizen  3 , Rob Klont  4 , Petra Brummelhuis-Visser  5 , Donald R A Uges  1 , Daan J Touw  1 , Jos G W Kosterink  1   6 , Tjip S van der Werf  7   8 , Jan-Willem C Alffenaar  9
Affiliations
Clinical Trial

Low Caspofungin Exposure in Patients in Intensive Care Units

Kim C M van der Elst et al. Antimicrob Agents Chemother. .

Abstract

In critically ill patients, drug exposure may be influenced by altered drug distribution and clearance. Earlier studies showed that the variability in caspofungin exposure was high in intensive care unit (ICU) patients. The primary objective of this study was to determine if the standard dose of caspofungin resulted in adequate exposure in critically ill patients. A multicenter prospective study in ICU patients with (suspected) invasive candidiasis was conducted in the Netherlands from November 2013 to October 2015. Patients received standard caspofungin treatment, and the exposure was determined on day 3 of treatment. An area under the concentration-time curve from 0 to 24 h (AUC0-24) of 98 mg · h/liter was considered adequate exposure. In case of low exposure (i.e., <79 mg · h/liter, a ≥20% lower AUC0-24), the caspofungin dose was increased and the exposure reevaluated. Twenty patients were included in the study, of whom 5 had a positive blood culture. The median caspofungin AUC0-24 at day 3 was 78 mg · h/liter (interquartile range [IQR], 69 to 97 mg · h/liter). A low AUC0-24 (<79 mg · h/liter) was seen in 10 patients. The AUC0-24 was significantly and positively correlated with the caspofungin dose in mg/kg/day (P = 0.011). The median AUC0-24 with a caspofungin dose of 1 mg/kg was estimated using a pharmacokinetic model and was 114.9 mg · h/liter (IQR, 103.2 to 143.5 mg · h/liter). In conclusion, the caspofungin exposure in ICU patients in this study was low compared with that in healthy volunteers and other (non)critically ill patients, most likely due to a larger volume of distribution. A weight-based dose regimen is probably more suitable for patients with substantially altered drug distribution. (This study has been registered at ClinicalTrials.gov under registration no. NCT01994096.).

Keywords: antifungal therapy; intensive care; pharmacokinetics; therapeutic drug monitoring.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Caspofungin concentration-time curve on day 3 of treatment, showing mean with standard deviation for each time point.
See this image and copyright information in PMC

References

    1. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177–186. doi:10.1086/321811. - DOI - PubMed
    1. Kullberg BJ, Arendrup MC. 2015. Invasive candidiasis. N Engl J Med 373:1445–1456. doi:10.1056/NEJMra1315399. - DOI - PubMed
    1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198–1208. doi:10.1056/NEJMoa1306801. - DOI - PMC - PubMed
    1. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis 74:323–323. doi:10.1016/j.diagmicrobio.2012.10.003. - DOI - PubMed
    1. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. 2011. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6:e24198. doi:10.1371/journal.pone.0024198. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources